Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

(This story was updated to accurately reflect the most current information.) OBETZ — Mount Gilead left nothing to chance this ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...

OBETZ — Mount Gilead's boys cross country team has enjoyed a decade of dominance unlike any high school sports program in the Marion area. Saturday was another link in the chain when MG won the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...